文献速递流行病学与生物统计真实世界研究与卫生经济

在坦桑尼亚比较三种双活性成分长效驱虫蚊帐与仅含拟除虫菊酯长效驱虫蚊帐抗疟效果与成本效果的四臂整群随机试验

Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial.
PubMed 文献 · Lancet · 2022-01-01

该四臂整群随机试验在坦桑尼亚米松圭开展,将84个整群随机分配至仅含α-氯氰菊酯、吡丙醚+α-氯氰菊酯、氯芬那吡+α-氯氰菊酯或胡椒基丁醚+氯菊酯蚊帐组。分配后24个月,氯芬那吡组疟疾感染患病率显著低于仅含拟除虫菊酯组(调整比值比0.45,95%CI 0.30-0.67,p=0.0001),且最具成本效果;吡丙醚组和胡椒基丁醚组与参照组无显著差异。

要点

  • 24个月时氯芬那吡组疟疾感染患病率25.6%,显著低于仅含拟除虫菊酯组的45.8%(调整比值比0.45,95%CI 0.30-0.67,p=0.0001)。
  • 吡丙醚组患病率37.5%(调整比值比0.79,95%CI 0.54-1.17,p=0.2354)和胡椒基丁醚组40.7%(0.99,95%CI 0.67-1.45,p=0.9607)与参照组无显著差异。
  • 氯芬那吡蚊帐最具成本效果,每避免一个伤残调整生命年公共提供方仅多花19美元(95%不确定性区间1-105),捐助方多花28美元(11-120)。

核心结论

  • 在存在拟除虫菊酯抗性蚊媒的地区,分配后2年氯芬那吡长效驱虫蚊帐比仅含拟除虫菊酯蚊帐提供显著更好的疟疾防护,其额外成本远低于可接受的成本效果阈值(每避免一个伤残调整生命年292-393美元)。
  • 在推广氯芬那吡蚊帐前,需要抗性管理策略以保持其有效性。
  • 胡椒基丁醚和吡丙醚蚊帐的织物和活性成分耐久性较差,可能与其相对标准蚊帐效果不足有关。

研究设计与样本

  • 四臂整群随机试验在坦桑尼亚米松圭开展,整群为村庄或村落地带组,每个整群核心区至少119户有6月龄至14岁儿童的家庭。
  • 采用约束随机化按1:1:1:1将整群分配至四类长效驱虫蚊帐:仅含α-氯氰菊酯(参照组)、吡丙醚+α-氯氰菊酯、氯芬那吡+α-氯氰菊酯、胡椒基丁醚+氯菊酯。
  • 每两人至少分发一顶长效驱虫蚊帐,社区成员和现场团队对分组分配设盲。
  • 2018年5月11日至7月2日纳入84个整群共39307户;2019年1月26日至28日向家庭分发147230顶长效驱虫蚊帐。
  • 主要结局为分配后24个月疟疾感染患病率,在意向治疗人群中比较各双活性成分蚊帐与仅含拟除虫菊酯蚊帐;主要经济结局为基于每避免一个伤残调整生命年的增量成本、模拟2年期的成本效果。

主要发现

  • 分配后3个月调查的4378名参与者中3155人(72.1%)报告使用研究蚊帐,24个月时降至21246人中的8694人(40.9%),各组下降率不同。
  • 24个月时疟疾感染患病率:仅含拟除虫菊酯参照组1199名儿童中549例(45.8%),吡丙醚组1258名中472例(37.5%,调整比值比0.79,95%CI 0.54-1.17,p=0.2354),胡椒基丁醚组1259名中512例(40.7%,0.99,95%CI 0.67-1.45,p=0.9607),氯芬那吡组1272名中326例(25.6%,0.45,95%CI 0.30-0.67,p=0.0001)。
  • 各组最常见报告的不良反应为皮肤刺激或感觉异常。
  • 氯芬那吡蚊帐最具成本效果,2年期内每避免一个伤残调整生命年,公共提供方多花19美元(95%不确定性区间1-105),捐助方多花28美元(11-120),从社会视角和家庭视角可节省成本。

临床怎么用

  • 作者认为,在推广氯芬那吡长效驱虫蚊帐前,需要抗性管理策略以保持其有效性。

局限性

  • 作者指出,胡椒基丁醚和吡丙醚长效驱虫蚊帐的织物和活性成分耐久性较差,可能与其相对标准蚊帐效果不足有关。
  • 作者指出,在推广氯芬那吡长效驱虫蚊帐前,需要抗性管理策略以保持其有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-lasting insecticidal nets (LLINs) have successfully reduced malaria in sub-Saharan Africa, but their effectiveness is now partly compromised by widespread resistance to insecticides among vectors. We evaluated new classes of LLINs with two active ingredients with differing modes of action against resistant malaria vectors. METHODS: We did a four-arm, cluster-randomised trial in Misungwi, Tanzania. Clusters were villages, or groups of hamlets, with at least 119 households containing children aged 6 months to 14 years living in the cluster's core area. Constrained randomisation was used to allocate clusters (1:1:1:1) to receive one of four types of LLIN treated with the following: α-cypermethrin only (pyrethroid-only [reference] group); pyriproxyfen and α-cypermethrin (pyriproxyfen group); chlorfenapyr and α-cypermethrin (chlorfenapyr group); or the synergist piperonyl butoxide and permethrin (piperonyl butoxide group). At least one LLIN was distributed for every two people. Community members and the field team were masked to group allocation. Malaria prevalence data were collected through cross-sectional surveys of randomly selected households from each cluster, in which children aged 6 months to 14 years were assessed for Plasmodium falciparum malaria infection by rapid diagnostic tests. The primary outcome was malaria infection prevalence at 24 months after LLIN distribution, comparing each of the dual-active-ingredient LLINs to the standard pyrethroid-only LLINs in the intention-to-treat population. The primary economic outcome was cost-effectiveness of dual-active-ingredient LLINs, based on incremental cost per disability-adjusted life-year (DALY) averted compared with pyrethroid-only LLINs, modelled over a 2-year period; we included costs of net procurement and malaria diagnosis and treatment, and estimated DALYs in all age groups. This study is registered with ClinicalTrials.gov (NCT03554616), and is ongoing but no longer recruiting. FINDINGS: 84 clusters comprising 39 307 households were included in the study between May 11 and July 2, 2018. 147 230 LLINs were distributed among households between Jan 26 and Jan 28, 2019. Use of study LLINs was reported in 3155 (72·1%) of 4378 participants surveyed at 3 months post-distribution and decreased to 8694 (40·9%) of 21 246 at 24 months, with varying rates of decline between groups. Malaria infection prevalence at 24 months was 549 (45·8%) of 1199 children in the pyrethroid-only reference group, 472 (37·5%) of 1258 in the pyriproxyfen group (adjusted odds ratio 0·79 [95% CI 0·54-1·17], p=0·2354), 512 (40·7%) of 1259 in the piperonyl butoxide group (0·99 [0·67-1·45], p=0·9607), and 326 [25·6%] of 1272 in the chlorfenapyr group (0·45 [0·30-0·67], p=0·0001). Skin irritation or paraesthesia was the most commonly reported side-effect in all groups. Chlorfenapyr LLINs were the most cost-effective LLINs, costing only US$19 (95% uncertainty interval 1-105) more to public providers or $28 (11-120) more to donors per DALY averted over a 2-year period compared with pyrethroid-only LLINs, and saving costs from societal and household perspectives. INTERPRETATION: After 2 years, chlorfenapyr LLINs provided significantly better protection than pyrethroid-only LLINs against malaria in an area with pyrethroid-resistant mosquitoes, and the additional cost of these nets would be considerably below plausible cost-effectiveness thresholds ($292-393 per DALY averted). Before scale-up of chlorfenapyr LLINs, resistance management strategies are needed to preserve their effectiveness. Poor textile and active ingredient durability in the piperonyl butoxide and pyriproxyfen LLINs might have contributed to their relative lack of effectiveness compared with standard LLINs. FUNDING: Joint Global Health Trials scheme (UK Foreign, Commonwealth and Development Office; UK Medical Research Council; Wellcome; UK Department of Health and Social Care), US Agency for International Development, President's Malaria Initiative.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Mosha JF, Kulkarni MA, Lukole E, et al. Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial. Lancet. 2022. PMID: 35339225. doi:10.1016/S0140-6736(21)02499-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。